Oncoptpeptides - Bring hope through science

Bringing hope through science

Released

Interim report Q1 2022

”Looking into 2022, I have confidence in our data and believe that science will prevail.”

CEO Jakob Lindberg

 

See the Webcast


For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

 

Q2 report August 11, 2022

Profile image

Presentation of the Q1 Report 2022

Oncopeptides published its report for the first quarter 2022 on May 4, 2022, and hosted a webcast on the same day at 11:00 CET. The event was hosted by CEO, Jakob Lindberg and members of the Oncopeptides' Leadership team. The presentation was held in English.

Link to the webcast and more information

Released

Annual Report 2021

Letter from the CEO - Science is leading the way

 

For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

Profile image
Jakob Lindberg, CEO

Letter from the CEO - Science is leading the way

"When I look back at 2021, this has been the most revolutionary year in Oncopeptides’ history"
Jakob Lindberg, CEO

Press release -

Oncopeptides publishes Q1 report 2022

Read press release
Events Oncopeptides

Upcoming events

View calendar

Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US

January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US.

Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).

The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.

More info, dial in numbers and the webcast link

Jakob interviewed by Di.TV - as new CEO about going forward

In conjunction with the anouncement of Jakob Lindberg as new CEO of Oncopeptides, he was interviewed by the Swedish economy TV channel Di.TV about the company's priorities going forward.

See the interview (Swedish) or read the transcript

Jakob Lindberg, CEO

Jakob Lindberg appointed CEO

On November 15, Oncopeptides announced that the Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides. Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.

Read the press release

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more

Released

Year-end report 2021

Confidence in our data leading the way forward

CEO Jakob Lindberg

 

See the Webcast                     


For further information, please contact:

Rolf Gulliksen
Global Head of Corporate Communications

 

Q1 report May 4, 2022

Profile image
Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Cultures & Values

We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.

Read more